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Background: Despite the breadth of studies demonstrating benefits of 
pneumococcal conjugate vaccine (pCV), uncertainty remains regarding the 
optimal pCV dosing schedule in infants.
Methods: We conducted a systematic literature review of pCV immuno-
genicity published from 1994 to 2010 (supplemented post hoc with studies 
from 2011). Studies included for analysis evaluated ≥2 doses of 7-valent or 
higher product (excluding Aventis-pasteur pCV11) administered to nonhigh-
risk infants ≤6 months of age. Impact of pCV schedule on geometric mean 
antibody concentration (GmC) and proportion of subjects over 0.35 mcg/ml 
were assessed at various time points; the GmC 1 month postdose 3 (for vari-
ous dosing regimens) for serotypes 1, 5, 6B, 14, 19F and 23F was assessed 
in detail using random effects linear regression, adjusted for product, acel-
lular diphtheria-tetanus-pertussis/whole-cell diphtheria- tetanus-pertussis 
coadministration, laboratory method, age at first dose and geographic region.
Results: From 61 studies, we evaluated 13 two-dose (2+0) and 65 three-
dose primary schedules (3+0) without a booster dose, 11 “2+1” (2 primary 
plus booster) and 42 “3+1” schedules. the GmC after the primary series 
was higher following 3-dose schedules compared with 2-dose schedules for 
all serotypes except for serotype 1. pre- and postbooster GmCs were gener-
ally similar regardless of whether 2 or 3 primary doses were given. GmCs 
were significantly higher for all serotypes when dose 3 was administered in 
the second year (2+1) compared with ≤6 months of age (3+0).
Conclusions: While giving the third dose in the second year of life pro-
duces a higher antibody response than when given as part of the primary 
series in the first 6 months, the lower GmC between the 2-dose primary 
series and booster may result in less disease protection for infants in that 
interval than those who completed the 3-dose primary series. theoretical 
advantages of higher antibodies induced by giving the third dose in the sec-
ond year of life, such as increased protection against serotype 1 disease, 
longer duration of protection or more rapid induction of herd effects, need 
to be evaluated in practice.
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Over 25% of the 7.6 million deaths occurring in children <5 years of age worldwide in 2010 were due to pneumonia, 
sepsis and meningitis.1 Streptococcus pneumoniae is a leading 
cause of these diseases, estimated by the World Health Organiza-
tion (WHO) to kill over 500,000 children in 20082; over 90% of 
these deaths occur in developing countries. three licensed pneu-
mococcal conjugate vaccines (pCVs) include antigens from 7, 10 
or 13 of the >91 known pneumococcal serotypes (pCV7, pCV10 
and pCV13), which account for many severe pneumococcal disease 
(pD)  episodes worldwide.3
pCVs are being introduced rapidly into an increasing num-
ber of countries, but the optimal dosing schedule(s) is unclear. the 
first widespread introduction was with pCV7 in the united States 
using a 4-dose schedule (3+1 administered at 2, 4, 6 and 12–15 
months of age); with this schedule, there has been virtual elimina-
tion of vaccine-type invasive pneumococcal disease (Vt-IpD) in 
children <5 years of age.4 However, not all countries use this sched-
ule or these ages for vaccine administration. Other pCV sched-
ules used around the world include 2 primary doses plus a booster 
(2+1) and 3 primary doses without a booster (3+0); for example, 
the united Kingdom schedule is at 2, 4 and 13 months of age and 
Australia uses a 2-, 4- and 6-month schedule. numerous studies 
have been conducted showing direct and indirect pCV7 efficacy 
and impact on disease given at various dosing regimens (reviewed 
in this supplement)5–8; similar studies are now being conducted on 
the more recently licensed pCV10 and pCV13 products. However, 
much is still unknown regarding an optimal schedule, which may 
vary by serotype, epidemiologic setting (ie, child mortality rate, 
community HIV prevalence or pneumococcal burden) and immu-
nization program characteristics (ie, vaccine coverage, timeliness). 
Furthermore, the impact of catch-up campaigns as part of pCV 
introduction on disease control is not characterized or fully under-
stood in its relationship to dosing schedule choices.
pCV regimens in use vary by number of doses, age at dos-
ing, interval between doses, use of a booster dose, pCV product 
and booster product [pCV vs. 23-valent pneumococcal polysaccha-
ride vaccine (ppV23)]. the optimum pCV schedule for a particular 
setting may depend not only on immunogenicity but also on the 
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routine immunization program, expected coverage rates and ages 
at actual vaccination.
the scientific community does not have consensus on 
which pCV schedules are optimal for a given epidemiologic set-
ting. Furthermore, there is no consensus on what gaps remain in 
the evidence base that would assist with policy development. Con-
sequently, we conducted a comprehensive, systematic review of 
available data evaluating the effect of pCV dosing schedules on 
immunogenicity, nasopharyngeal carriage, IpD, pneumonia and 
indirect effects. the aim of this work was to provide the evidence 
base for a strategic analysis of key information gaps required to 
guide pCV policy development in relation to the WHO’s expanded 
programme for Immunization schedule. Results for the clinical 
outcomes are presented elsewhere.5–8. In this report, we assessed 
the effects on immunogenicity of the number of pCV doses, inter-
val between doses, age at dosing, timing of a third dose and impact 
of a booster dose.
METHODS
Literature Search
this analysis is part of a larger project describing the impact 
of pCV dosing schedules on IpD, immunogenicity, nasopharyngeal 
carriage, pneumonia and indirect effects.5–8 Details on the litera-
ture search terms and methods used in this systematic review are 
described in the methods Appendix.9 In brief, a systematic literature 
review was performed to collect all available english language data 
published from January 1994 to September 2010 (supplemented 
post hoc with studies from 2011) on the effect of various pCV vac-
cination schedules among immunized children on immunogenicity, 
np colonization, IpD, pneumonia and on indirect effects among 
unvaccinated populations. Articles published in 14 databases, 
from ad hoc unpublished sources and abstracts from meetings 
of the International Symposium on pneumococci and pneumo-
coccal Disease (1998–2010) and the Interscience Conference on 
Antimicrobial Agents and Chemotherapeutics (1994–2010), were 
searched. We included all randomized-controlled clinical trials, 
nonrandomized trials, surveillance database analyses and obser-
vational studies of any pCV schedule on 1 or more outcomes of 
interest. Studies were included for abstraction if ppV was used as 
a booster dose, but not as a primary dose. titles and abstracts were 
reviewed twice and those with relevant content on 1 of the 5 out-
comes (immunogenicity, carriage, invasive disease, pneumonia and 
indirect effects) underwent full review using a standardized data 
collection instrument. Details on the search methods are provided 
in the methods Appendix.9
Data Abstraction
Citations recovered through the literature search went 
through several stages of independent review to determine their 
eligibility, as described earlier. Citations meeting inclusion criteria 
were categorized on an outcome-specific basis into “study families,” 
where each family included abstracts or publications generated from 
a single protocol, population, surveillance system or other data col-
lection system relevant to that outcome. Investigators identified pri-
mary data from the individual studies making up each study family 
for inclusion in the analysis. the primary data were selected as the 
most current and complete data available for that study family. In 
some cases, these data were drawn from more than one publication 
within a family. We also defined “study arms” as a group of children 
distinguished by immunization schedule or pCV product.
We abstracted core information on the following: number 
of children in a “study arm”; pCV manufacturer, valency and 
conjugate protein; coadministered vaccines; country; age at each 
dose and date of study and publication. Additional data abstracted 
for the immunogenicity outcome included antibody levels; age at 
each dose and blood draw and antibody assay methods. Geomet-
ric mean antibody concentration (GmC) with confidence interval 
was abstracted for immunoglobulin G (IgG) antibody determined 
by enzyme-linked immunoabsorbent assay (elISA). We also 
abstracted the percentage of children with serotype-specific IgG 
concentration >0.35 µg/ml [or >0.2 µg/ml if the GlaxoSmithKline 
elISA method was used (GSK, middlesex, united Kingdom)], 
defined previously as the correlate of observed efficacy for Vt-
IpD across the randomized trials.10–13 Results of other assays were 
abstracted if performed, such as opsonophagocytic assay (OpA) 
and avidity. If age at vaccination for pCV product or coadminis-
tered vaccines were not described, recommended ages for receiving 
doses from that country’s national immunization plan for the year 
when the study was conducted were used.
Inclusion and Exclusion Criteria
Study arms meeting the following criteria were included in 
analyses: subjects immunized with at least 2 doses of pCV, with 
the first dose ≤4 months and last primary dose ≤6 months of age; 
licensed pCV with 7 or more antigens, or unlicensed pCV but suf-
ficiently similar to a licensed pCV, and elISA IgG GmC or per-
centage >0.35 µg/ml (or >0.2 µg/ml if GSK elISA method used) 
provided for any of the 6 serotypes of interest (1, 5, 6B, 14, 19F and 
23F). Data following immunization with ppV23 were excluded. 
Results from populations at high risk for pD were excluded (ie, 
HIV-infected, sickle cell disease, those with chronic illness and 
indigenous populations). Antibody responses to serotypes 1 and 
5 were excluded from analyses for pCVs not containing these 
serotypes (eg, pCV7, pCV8). Antibody responses to the Aventis 
pCV11 were substantially higher than those of other pCV products 
and studies of this product were limited to a 3-dose primary series 
schedule; therefore, we excluded studies of Aventis pCV11 because 
they obscured our ability to assess the effect of dosing schedule on 
the antibody response.
Pneumococcal Vaccine Dosing Schedules
Any study arm with immunogenicity data after a second pri-
mary dose, including study arms eventually receiving a third pri-
mary dose, was defined as “2 primary doses”; “3 primary doses” 
was defined as any study arm with immunogenicity data after a 
third primary dose, whether a booster dose was given. Schedules 
“2+0” and “2+1” refer to 2 primary doses without and with 1 pCV 
booster dose, respectively; “3+0” and “3+1” schedules refer to 3 
primary doses without and with 1 pCV booster dose, respectively. A 
booster dose was defined as immunization with pCV between 9 and 
18 months of age in infants who had completed a 2-dose or 3-dose 
primary series. mean age at immunization, if available, defined age 
at each dose; otherwise, scheduled age was used. to collapse into 
schedules, age was rounded to the nearest 2 weeks. Interval between 
doses was determined by number of months between first and sec-
ond primary dose; all but 1 study retained the same interval between 
first and second as between second and third primary doses.
Data Analysis
Because most studies did not directly compare 1 pCV dosing 
schedule to another, we followed an ecological regression approach 
to compare dosing schedules across studies. We fitted random 
effects meta-regression models of log-transformed GmC levels by 
serotype, weighting by the inverse of their variances, to account for 
intrastudy variation for studies assessing more than one study arm. 
We calculated robust standard errors to account for multiple arms 
within studies.14,15 We adjusted for study-specific covariates: age at 
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first dose, geographic region, pCV product, type of coadministered 
diphtheria-tetanus-pertussis (Dtp) vaccine [ie, whole-cell (Dtwp) 
vs. acellular (Dtap) pertussis], and elISA method. For compari-
sons of immunogenicity at different time points, such as postpri-
mary versus postboost and preboost versus postboost, only studies 
with data for both time points were included in the analyses. For 
studies that did not report the variance of the GmC (between 10% 
and 18% among analyses), we assigned the median of the variances 
reported by studies with the same region, coadministered Dtp vac-
cine and age at first dose. to investigate the effect of this simple 
imputation approach, we conducted analyses with and without the 
studies missing variance; there was no association between absence 
of variance estimates and GmC.
to calculate 95% confidence intervals for the proportion of 
children with antibody concentrations above the cut-off, we used the 
normal approximation interval with proportion (p)=(X+2)/(n+4), 
a near approximation to the Wilson interval method, which is valid 
for extreme values (ie, p = 100%).16,17
Statistical significance was defined as P < 0.05; there was 
no adjustment for multiple testing. SAS version 9.2 (SAS Institute 
Inc., Cary, nC) was used for all analyses.
RESULTS
Of 12,980 citations reviewed, we identified 113 with immu-
nogenicity data, of which 61 had data relevant for analysis.18–78 more 
studies evaluated 3-dose primary schedules than 2-dose primary 
schedules (table 1); every geographic region evaluated a 3-dose 
primary schedule, whereas there were no 2-dose primary sched-
ules evaluated in the latin America/Caribbean region. Only europe 
evaluated 1 booster dose following 2 primary doses (2+1), whereas 
all but Oceania evaluated 3+1 schedules. most studies (74%) evalu-
ated pCV7 and few (21%) evaluated pCVs with serotypes 1 and 5. 
TABLE 1. Characteristics of Studies and Study Arms by Number of Primary Doses and Schedule
Study Arms* by Dose Schedule Arms with Postdose GMC Data† Studies‡ 
2 + 0§ (N = 13) 2 + 1 (N = 11) 3 + 0 (N = 65) 3 + 1 (N = 42) 2 doses (N = 25) 3 doses (N = 86) (N = 61)
Region¶
  Africa 3 0 6 3 3 8 6
  Asia 2 0 13 3 4 12 9
  Oceania 2 0 2 0 1 1 1
  Europe 3 11 24 26 12 40 30
  North America 3 0 18 9 5 21 13
  Latin America/
Caribbean.
0 0 4 1 0 4 3
Publication year‖
  1994–1998 2 0 5 2 2 5 5
  1999–2002 2 0 14 9 5 19 12
  2003–2006 1 3 7 16 6 22 16
  2007–2010 6 8 39 13 11 37 26
  2011 2 0 2 2 1 3 2
ELISA method**
  Wyeth/Other 12 10 55 28 23 66 49
  GSK 1 1 12 14 2 20 13
PCV product
  Wyeth-7 6 7 37 20 11 42 38
  Wyeth-9 3 2 9 3 5 11 7
  Wyeth-13 (Pfizer) 0 1 4 0 1 2 3
  GSK-10 1 1 6 7 2 10 9
  GSK-11 0 0 1 3 0 4 3
  Aventis-8 0 0 6 2 4 8 4
  Merck-7 3 0 4 7 2 9 7
Coadministered DTP vaccine
  DTaP 5 11 22 23 12 32 32
  DTwP 8 0 43 19 13 53 30
Interval between doses 1 and 2
  1 month 5 2 36 14 8 36 29
  2 months 8 9 31 28 17 50 40
Age first dose
  Birth 0 0 0 1 0 1 1
  6 weeks 3 0 6 2 3 7 6
  2 months 8 4 52 36 14 69 47
  3 months 1 7 7 3 5 7 9
  4 months 1 0 2 0 3 2 2
*A study may present immunogenicity data for 1 or more groups of children, defined as study arms. Study arms may be distinguished by immunization schedule (eg, 2-dose vs. 
3-dose schedule or age at first dose) or PCV product (eg, PCV10 vs. PCV7).
†"2 doses” summarizes study arms with immunogenicity GMC data after a second primary dose, regardless of whether a third primary dose or booster dose was given; “3 doses” 
summarizes study arms with immunogenicity GMC data after a third primary dose, regardless of whether a booster dose was given. A study arm with immunogenicity data after a 
second and third dose will appear in both columns. Numbers describe only study arms with GMC data.
§2 + 0, 2 primary doses without a booster dose; 2 + 1, 2 primary doses plus a booster dose; 3 + 0, 3 primary doses without a booster dose; 3 + 1, 3 primary doses plus a booster dose. 
Arms that received a different product for the third or fourth dose than was administered in the first 2 or 3 doses (eg, boosted with PPV23) are described as “2 + 0” and “3 + 0,” respec-
tively. Numbers describe study arms with either GMC or proportion above specific value.
‡Number of unique studies with at least 1 study arm for the indicated characteristic.
¶Regions were defined by UN region.79
‖Year study conducted was not specified for most studies, so publication year is presented instead.
**The “Wyeth/other” method included any laboratory method other than the GSK laboratory method.
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FIGURE 1. Effect of primary PCV dosing schedule on GMC by serotype. A) 2-dose versus 3-dose primary schedule on 
postprimary (~7 months) GMC; B) 2-dose versus 3-dose primary schedule on preboost (~12 months) GMC; C) effect of 
2-dose versus 3-dose primary schedule on postboost (~13 months) GMC; D) effect of delaying age at first dose by 1 month 
on postprimary (~7 months) GMC; E) effect of increasing the interval between doses from 1 to 2 months on postprimary (~7 
months) GMC and F) effect of delaying age at last dose by 1 month on postprimary (~7 months) GMC. Adjusted for age at first 
dose, geographic region, PCV product, coadministration of DTaP versus DTwP and laboratory method (GSK vs. Wyeth/other). 
N is the number of study arms. Asterick indicates that the significant ST1 finding in Figure 1B is due to 1 study where the two 
2-dose arms had lower GMCs than the two 3-dose arms.33 Otherwise, when looking at other studies, there is no difference.
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the GSK elISA method was used to evaluate postprimary GmCs 
in all GSK pCV10 study arms, 4 of 7 GSK pCV11 study arms, 11 
of 72 pCV7 study arms and no (0/54) study arms of other products. 
Very few studies reported avidity or functional OpA responses to 
evaluate the effect of number of doses on those outcomes. Immu-
nogenicity varied by region, pCV product, coadministration with 
Dtap (St14 only) and elISA method.80 Schedule effects were 
adjusted for these covariates in all analyses.
2-dose Versus 3-dose Priming Schedules
Of 61 studies included in the 2-dose versus 3-dose primary 
series analysis, 6 directly compared these different schedules and 9 
additional studies provided after dose 2 results for 13 study arms 
eventually receiving a third primary dose. GmC results were avail-
able for 25 two-dose and 86 three-dose study arms (table 1). the 
3-dose primary schedule produced significantly higher postprimary 
GmC antibody response than the 2-dose schedule for all except 
serotype 1 (Fig. 1A,B). However, the number of primary doses did 
not meaningfully affect GmCs measured in the second year of life 
[ie, prebooster (Fig. 1B) or postbooster GmCs (Fig. 1C)], except 
the postboost response to serotype 6B, which was significantly 
higher in children who received 3 primary doses.
Timing of Primary Schedule
We evaluated the age at first dose, interval between doses and 
age at last dose, while adjusting for whether 2 or 3 primary doses were 
administered; albeit, each is a factor of the other 3 so they cannot be 
disentangled entirely. Administering the first dose at 1 month of age (eg, 
at 3 months vs. 2 months of age) did not meaningfully affect the postpri-
mary GmCs (Fig. 1D). However, increasing the interval between doses 
from 1 to 2 months significantly increased the postprimary GmCs for 
serotypes 6B, 14 and 23F (Fig. 1e). Increasing the age at last dose had 
a similar effect to increasing months between doses although the effect 
size was smaller and did not reach statistical significance (Fig. 1F). 
Among the studies in the meta-analysis, only one directly compared 
interval of dosing while holding age at first dose constant, and it did so 
in a randomized trial setting.33 that study’s findings support the meta-
analysis results; it showed that children randomly assigned to a 2-month 
interval between 2 primary doses had significantly higher postprimary 
GmCs for serotypes 6B, 14 and 23F and preboost GmCs at 1 year of 
age for serotypes 4, 6B and 23F compared with children who received 
their 2 primary doses with 1-month interval.
Booster Dose Effect
Of 53 study arms evaluating a pCV booster dose (generally 
in the second year of life), 11 (21%) had received a 2-dose primary 
schedule and 42 (79%) a 3-dose primary schedule. the booster 
dose increased GmCs from pre- to postbooster for all serotypes 
regardless of the priming schedule (Fig. 3A). postbooster GmCs 
(mean age 13.5 months) were also significantly higher than postpri-
mary GmC (mean age 7.2 months) for all serotypes regardless of 
the priming schedule (Fig. 3B).
3+0 Versus 2+1 Schedules
there were 58 studies with immunogenicity data on 2+1 
or 3+0 schedules; GmC results were available for 86 “3+0” and 
FIGURE 2. Log GMC by serotype, geographic region and number of primary series PCV doses. PCV product is indicated 
by manufacturer [W, Wyeth (Pfizer); G, GSK; A, Aventis; M, Merck] and valency (ie, number of serotypes it contains) on the 
x-axis, and by (o) for licensed or precursor or (+) for unlicensed product.
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11 “2+1” study arms. the unadjusted median postbooster GmC 
response (in µg/ml) of 2+1 schedules (median age at blood draw 
12.5 months) compared with the postprimary response of 3+0 
schedules (median age at blood draw 7.0 months) was 5.1 versus 
2.5, 3.4 versus 3.0, 7.4 versus 1.4, 12.0 versus 4.7, 7.7 versus 3.6, 
4.5 versus 1.7 for serotypes 1, 5, 6B, 14, 19F and 23F, respectively. 
After adjusting for geographic region, age at first dose, coadminis-
tration of Dtap versus Dtwp, pCV product and elISA laboratory 
method, the mean 2+1 postbooster antibody response (median age 
at blood draw 12.5 months) was significantly higher than the 3+0 
postprimary response (median age at blood draw 7.0 months) for 
all serotypes (Figs. 4 and 5), although the covariates are tightly cor-
related and so confounding might not be entirely controlled for.
Proportion Achieving IPD Correlate of Protection 
Cut-off
the percentage of children with IgG antibody concentra-
tions >0.35 µg/ml (or >0.20 µg/ml for GSK elISA) was high 
and comparable for both 2-dose and 3-dose primary schedules for 
all serotypes except for 6B and 23F (Fig. 6). For these serotypes, 
the proportion of children above the threshold was higher for those 
receiving a 3-dose than a 2-dose primary schedule; 17/24 (70.8%) 
3-dose study arms reported over 80% of subjects above the cut-off 
for serotype 6B compared with 3/13 (23.1%) 2-dose study arms. 
For serotype 23F, results were 21/24 (87.5%) compared with 4/11 
(36.4%), respectively.
Only one 2+1 study presented percentage response data fol-
lowing the booster dose, which showed >96% response (IgG anti-
body concentrations ≥0.2 µg/ml) using the GSK elISA for all 
serotypes except for 6B which had 88% response; response was 
also high (>87% for all serotypes) using the 0.35 µg/ml cut point.72
DISCUSSION
In general, a 3-dose primary schedule induced higher anti-
body than a 2-dose schedule for most serotypes assessed and a 
booster dose induced higher antibodies over those following the 
primary dose schedule for all serotypes. the degree to which 
higher antibody concentrations are important for protecting against 
serious disease is not established; there may be a threshold above 
which higher circulating antibody concentrations are not mean-
ingfully more protective for an individual. While the aggregate, 
population-based correlate of protection used to license new pCV 
vaccines is 0.35 µg/ml, higher IgG levels may be important in 
protecting against np colonization, conferring herd immunity, pro-
longing individual protection and, up to a point, may correlate at 
the individual level with disease protection. It is likely that the true 
threshold will vary by both serotype and disease syndrome, with 
higher concentrations probably required for mucosal infection like 
nonbacteremic pneumonia compared with systemic infection like 
invasive pneumococcal sepsis.
While both 2+1 and 3+0 schedules show evidence of robust 
immunogenicity for the serotypes evaluated (1, 5, 6B, 14, 19F and 
23F), determining which schedule produced a superior response for 
serotypes 1 and 5 was not possible because data were limited, espe-
cially for 2+1 regimens (n = 4 study arms). In addition, the anal-
yses for serotypes 1 and 5 included mostly studies of unlicensed 
formulations. Restricting analyses for serotypes 1 and 5 to only 
licensed products (ie, GSK pCV10 and Wyeth pCV13) provided 
very few studies for analysis: there was only one 2+1 study for 
each GSK pCV10 and Wyeth pCV13, and 6 and four 3+0 studies, 
respectively).
Considering options for a 3-dose schedule, which is rec-
ommended by the WHO and for which GAVI Alliance funding is 
A
B
FIGURE 3. Effect of PCV booster dose in second year 
of life on GMC by serotype. A) Change in GMC pre- to 
postbooster; B) Change in GMC from postprimary (~7 
months) to postbooster (~13 months).
FIGURE 4. Difference in post-third dose GMC when 
changing from 3+0 (GMC at 6 months) to 2+1 (GMC at 15 
months) PCV schedule.
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FIGURE 5. After postdose-3 log GMC, by serotype and PCV schedule: 2+1 (postbooster) versus 3+0 (postprimary).  
PCV product is indicated by manufacturer and valency (ie, number of serotypes it contains). W, Wyeth (Pfizer); G, GSK;  
A, Aventis; M, Merck. 
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available for resource-limited countries, administering the third 
dose as a booster in the second year of life (2+1) induced higher 
antibodies than using the third dose to complete a primary series 
(3+0). However, for many epidemiologic settings, the first year of 
life is a time of high disease burden, so the advantage of delaying 
the third dose until the age of 1 year to achieve higher responses may 
be offset by the risk of leaving infants relatively at risk with lower 
antibodies after 2 primary doses.
While the use of meta-analysis allowed us to incorporate data 
from a large number of studies, controlling for study differences in 
covariates and confounding factors is a challenge in meta-analyses. 
Head-to-head studies that directly compare different schedules are 
more robust since they inherently control for potential confounders by 
keeping all covariates the same except the schedule, ideally through 
randomization. there were only 6 head-to-head randomized con-
trolled trials that evaluated 2-dose versus 3-dose primary schedules. 
these were systematically reviewed in detail by investigators at the 
university of Berne who found that 3 primary doses provided higher 
antibody concentrations compared with 2 primary doses.81 While 
there was representation across regions and a variety of schedules 
evaluated, their analysis was limited to just these 6 trials and all but 
1 evaluated 3-dose schedules with a 1-month interval between doses 
compared with 2-dose schedules with a 2-month interval between 
doses (ie, age at dosing was 2 and 4 vs. 2, 3, and 4 months); dos-
ing interval, therefore, confounds the relationship between antibody 
response and number of doses administered in that analysis. Our 
analyses included an additional 13 study arms where the antibody 
response after dose 2 was compared with that after dose 3 in the same 
individual. We also included a wealth of immunogenicity data avail-
able from studies evaluating only one schedule. Our more inclusive 
analyses reinforce the findings from the university of Berne analysis 
of head-to-head trials that not only 3 primary doses provide improved 
immunogenicity compared with 2 primary doses for most serotypes, 
but also enabled assessment of schedule effects in a broader variety 
of settings and combinations and enabled assessment of the timing of 
doses with respect to age at administration and months between doses.
Because most of the analysis was based on between-study 
comparisons rather than direct comparisons within a study, control-
ling for potential confounders of immunogenicity is essential when 
drawing inferences about dosing schedule effects. For some analy-
ses, covariates such as coadministration of Dtap versus Dtwp or 
the interval between doses (eg, 6, 10 and 14 weeks vs. 2, 4 and 6 
months) could not be completely adjusted for because these factors 
are region specific and therefore linked. We could only compare 
2+1 and 3+0 schedules within europe because there were no eli-
gible 2+1 schedule studies from other regions. Disentangling the 
effect of number of doses from the effect of age at each immu-
nization or interval between primary doses is nearly impossible 
because as one factor changes necessarily at least one more also 
has to change.
FIGURE 6. Proportion of children achieving >0.35 μg/mL (or >0.2 μg/mL if GSK ELISA used), by serotype, number of doses 
in primary series and immunization schedule. Each bar represents results from one study arm. Schedule is noted on the y-axis 
in months (m) or weeks (w). Error bars are 95% confidence intervals.
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Serum IgG antibody concentration ≥0.35 μg/ml 
(or ≥0.20 μg/ml for studies using the GSK elISA) after the pri-
mary series is considered a correlate for licensure of pCV prod-
ucts as they predict aggregate vaccine efficacy against vaccine 
serotype IpD among the immunized population.13 We observed the 
same trend in the percentage meeting this cutoff for the 2-dose and 
3-dose priming schedules as with GmCs but with less differentia-
tion between these 2 schedules. It is our assessment that GmC is a 
more finely differentiating metric of the various dosing schedules 
than the proportion above the licensure threshold; however, it is 
not known which measure is more meaningful and predictive of 
clinical impact. We emphasize GmC values for several reasons. 
First, the population level protection effects are dependent on np 
colonization. preventing pneumococcal colonization is critical for 
population benefits of a pneumococcal vaccination program, since 
protection against colonization will necessarily mean protection 
against disease as well as reduced transmission in the commu-
nity. Studies evaluating the correlation of antibody and protection 
against np colonization have shown that antibody concentrations 
in the range of 4–5 µg/ml correlate with protection, although this 
is likely a marker of immune response and not the direct effector of 
protection.82–84 Second, the prevention of pneumococcal pneumonia 
is the primary syndrome of concern for pCV programs, since most 
pneumococcal deaths that occur in young children globally are due 
to pneumonia, and the threshold for prevention of pneumococcal 
pneumonia is estimated to be significantly > 0.35 μg/ml (K.l.O.B. 
and G.D., unpublished data). third, given the mucosal nature of 
pneumococcal pneumonia (when compared with IpD syndromes), 
it is not entirely clear whether circulating antibody or mucosal 
cells are the more important effector molecule for its prevention, 
although passive antibody studies (eg, studies evaluating adminis-
tration of bacterial polysaccharide immunoglobulin) would argue 
for a role of circulating pneumococcal serum antibody.85 Func-
tional OpA may be a better predictor of protection than serum IgG; 
however, few studies assessed functional responses, so we were 
restricted to evaluating dosing schedule impact on serum IgG.
this, the largest such analysis of existing pCV immuno-
genicity data conducted to date, contributed to the WHO Strategic 
Advisory Group of experts statement regarding optimizing pCV 
dosing schedules86 and will help to guide pCV policy development 
in relation to the WHO’s expanded programme for Immunization 
schedule. We have shown improved immunogenicity for 3 doses 
compared with 2 doses for most serotypes when serum IgG GmC 
is used as the metric for comparison. As expected, the 2+1 sched-
ule leads to significantly higher antibody concentrations following 
the third dose, because it is administered remote from the primary 
series and acts as a booster dose when compared with the 3+0 
schedule where the third dose is administered in the primary series. 
the tradeoff, therefore, is fundamentally between higher antibody 
concentrations in the second year of life following the booster with 
a 2+1 schedule and higher antibody concentrations in the first year 
of life from a 3-dose instead of a 2-dose primary schedule. While 
the relative merits of these 2 approaches will likely vary by sero-
type, disease syndrome and vaccine program, in practice, the herd 
effects induced by a successful vaccination program may minimize 
the impact on disease burden caused by schedule-related differ-
ences in immune response.
ACKNOWLEDGMENTS
The authors gratefully acknowledge the tremendous support 
for abstracting data from the following: Becky Roberts, Karrie-Ann 
Toews and Carolyn Wright from the Centers for Disease Control 
and Prevention, Respiratory Diseases Branch; Catherine Bozio, 
Rose Chang, Jamie Felzer, Amy Fothergill, Sara Gelb, Kristen 
Hake, Sydney Hubbard, Grace Hunte and Shuling Liu from Emory 
University Rollins School of Public Health; and Bethany Baer, 
Stephanie Davis, Sylvia Kauffman, Min Joo Kwak, Paulami Naik 
and Meena Ramakrishnan from The Johns Hopkins Bloomberg 
School of Public Health.
REFERENCES
 1. liu l, Johnson Hl, Cousens S, et al.; Child Health epidemiology Reference 
Group of WHO and unICeF. Global, regional, and national causes of child 
mortality: an updated systematic analysis for 2010 with time trends since 
2000. Lancet. 2012;379:2151–2161.
 2. World Health Organization and unICeF. Global immunization data. 
October 2012. Available at: http://www.who.int/immunization_monitoring/
Global_Immunization_Data.pdf. p. 2. Accessed February 4, 2013.
 3. Johnson Hl, Deloria-Knoll m, levine OS, et al. Systematic evaluation of 
serotypes causing invasive pneumococcal disease among children under five: 
the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.
 4. pilishvili t, lexau C, Farley mm, et al.; Active Bacterial Core Surveillance/
emerging Infections program network. Sustained reductions in inva-
sive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 
2010;201:32–41.
 5. Conklin l, loo JD, Kirk J, et al. Systematic review of the effect of pneu-
mococcal conjugate vaccine dosing schedules on vaccine-type invasive 
pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33 
(Suppl 2):S109–S118.
 6. Fleming-Dutra Ke, Conklin l, loo JD, et al. Systematic review of the effect 
of pneumococcal conjugate vaccine dosing schedules on vaccine-type naso-
pharyngeal carriage. Pediatr Infect Dis J. 2014;33 (Suppl 2):S152–S160.
 7. loo JD, Conklin l, Fleming-Dutra Ke, et al. Systematic review of the effect 
of pneumococcal conjugate vaccine dosing schedules on prevention of 
pneumonia. Pediatr Infect Dis J. 2014;33 (Suppl 2):S140–S151.
 8. Davis S, Deloria Knoll m, O’Brien Kl; for the pneumococcal Carriage 
Group (pneumoCarr), and the pCV Dosing landscape project. Impact of 
pneumococcal conjugate vaccines on nasopharyngeal and invasive dis-
ease among unvaccinated people: review of evidence on indirect effects. 
Vaccine. [published online ahead of print may 16, 2013]. doi: 10.1016/j.
vaccine.2013.05.005.
 9.  loo JD, Conklin l, Deloria Knoll m, et al. methods for a systematic review 
of pneumococcal conjugate vaccine dosing schedules. Pediatr Infect Dis J. 
2014;33 (Suppl 2):S182–S187.
 10. World Health Organization. Recommendations to assure the quality, safety 
and efficacy of pneumococcal conjugate vaccines: proposed replacement 
of TRS 927, Annex 2, ECBS. October 2009. Available at: http://www.who.
int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.html. 
Accessed February 4, 2013.
 11. World Health Organization. Recommendations for production and control 
of pneumococcal conjugate vaccines. WHO Technical Report Series 927, 
Annex 2. 2005. Available at: http://www.who.int/biologicals/publications/
trs/areas/vaccines/pneumo/AnneX%202%20pneumococcalp64-98.pdf. 
Accessed February 4, 2013.
 12. Henckaerts I, Goldblatt D, Ashton l, et al. Critical differences between 
pneumococcal polysaccharide enzyme-linked immunosorbent assays with 
and without 22F inhibition at low antibody concentrations in pediatric sera. 
Clin Vaccine Immunol. 2006;13:356–360.
 13. Jódar l, Butler J, Carlone G, et al. Serological criteria for evaluation and 
licensure of new pneumococcal conjugate vaccine formulations for use in 
infants. Vaccine. 2003;21:3265–3272.
 14. Jackson D, White IR, thompson SG. extending DerSimonian and laird’s 
methodology to perform multivariate random effects meta-analyses. Stat 
Med. 2010;29:1282–1297.
 15. DerSimonian R, laird n. meta-analysis in clinical trials. Control Clin 
Trials. 1986;7:177–188.
 16. newcombe RG. two-sided confidence intervals for the single proportion: 
comparison of seven methods. Stat Med. 1998;17:857–872.
 17. Wilson eB. probable inference, the law of succession, and statistical infer-
ence. JASA 1927; 22: 209–212.
 18. Anderson el, Kennedy DJ, Geldmacher Km, et al. Immunogenicity of hep-
tavalent pneumococcal conjugate vaccine in infants. J Pediatr. 1996;128(5 
pt 1):649–653.
Deloria Knoll et al The Pediatric Infectious Disease Journal • Volume 33, Number 1, Supplement 2, January 2014
S128  |  www.pidj.com  © 2013 Lippincott Williams & Wilkins
 19. Anttila m, eskola J, Ahman H, et al. Differences in the avidity of antibodies 
evoked by four different pneumococcal conjugate vaccines in early child-
hood. Vaccine. 1999;17:1970–1977.
 20. Bermal n, Szenborn l, Chrobot A, et al. the 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine (pHiD-CV) 
coadministered with Dtpw-HBV/Hib and poliovirus vaccines: assessment 
of immunogenicity. Pediatr Infect Dis J. 2009;28(4 suppl):S89–S96.
 21. Black S, Shinefield H, Fireman B, et al. efficacy, safety and immunogenic-
ity of heptavalent pneumococcal conjugate vaccine in children. northern 
California Kaiser permanente Vaccine Study Center Group. Pediatr Infect 
Dis J. 2000;19:187–195.
 22. Block Sl, Hendrick JA, Smith RA, et al. pneumococcal conjugate vac-
cine (pCV) vs. pneumococcal polysaccharide 23 (pn23) in 6 month old 
infants after 2 prior doses of pCV. In: American Society for Microbiology. 
Abstracts of the 37th Interscience Conference on Antimicrobial Agents & 
Chemotherapy (ICAAC); 1997; Canada: toronto, Ontario. p. 208.
 23. Bryant KA, Block Sl, Baker SA, et al.; pCV13 Infant Study Group. Safety 
and immunogenicity of a 13-valent pneumococcal conjugate vaccine. 
Pediatrics. 2010;125:866–875.
 24. Buttery Jp, Riddell A, mcVernon J, et al. Immunogenicity and safety of 
a combination pneumococcal-meningococcal vaccine in infants: a rand-
omized controlled trial. JAMA. 2005;293:1751–1758.
 25. Choo S, Seymour l, morris R, et al. Immunogenicity and reactogenicity 
of a pneumococcal conjugate vaccine administered combined with a hae-
mophilus influenzae type B conjugate vaccine in united Kingdom infants. 
Pediatr Infect Dis J. 2000;19:854–862.
 26. Dicko A, Odusanya OO, Diallo AI, et al. primary vaccination with the 
10-valent pneumococcal non-typeable Haemophilus influenzae protein D 
conjugate vaccine (pHiD-CV) in infants in mali and nigeria: a randomized 
controlled trial. BMC Public Health. 2011;11:882.
 27. Durando p, Crovari p, Ansaldi F, et al.; Collaborative Group for 
pneumococcal Vaccination in liguria. universal childhood immunisation 
against Streptococcus pneumoniae: the five-year experience of liguria 
Region, Italy. Vaccine. 2009;27:3459–3462.
 28. eick A, Croll J, Weatherholtz R, et al. Safety and immunogenicity of two 
octavalent pneumococcal conjugate vaccines in American Indian infants. 
Vaccine. 2004;22:1260–1264.
 29. ekström n, Ahman H, Verho J, et al. Kinetics and avidity of antibod-
ies evoked by heptavalent pneumococcal conjugate vaccines pncCRm 
and pncOmpC in the Finnish Otitis media Vaccine trial. Infect Immun. 
2005;73:369–377.
 30. esposito S, pugni l, Bosis S, et al. Immunogenicity, safety and tolerability 
of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 
11 months post-natally to pre- and full-term infants. Vaccine. 2005;23: 
1703–1708.
 31. esposito S, tansey S, thompson A, et al. Safety and immunogenicity of 
a 13-valent pneumococcal conjugate vaccine compared to those of a 
7-valent pneumococcal conjugate vaccine given as a three-dose series with 
routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 
2010;17:1017–1026.
 32. Givon-lavi n, Greenberg D, Dagan R. Immunogenicity of alternative regi-
mens of the conjugated 7-valent pneumococcal vaccine: a randomized con-
trolled trial. Pediatr Infect Dis J. 2010;29:756–762.
 33. Goldblatt D, Southern J, Ashton l, et al. Immunogenicity of a reduced 
schedule of pneumococcal conjugate vaccine in healthy infants and corre-
lates of protection for serotype 6B in the united Kingdom. Pediatr Infect 
Dis J. 2010;29:401–405.
 34. Goldblatt D, Southern J, Ashton l, et al. Immunogenicity and boosting after 
a reduced number of doses of a pneumococcal conjugate vaccine in infants 
and toddlers. Pediatr Infect Dis J. 2006;25:312–319.
 35. Huebner Re, mbelle n, Forrest B, et al. Immunogenicity after one, two or 
three doses and impact on the antibody response to coadministered anti-
gens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, 
South Africa. Pediatr Infect Dis J. 2002;21:1004–1007.
 36. Jonsdottir I, Sigurdardottir St, Gudnason t, et al. Concomitant administra-
tion of octavalent pneumococcal polysaccharide conjugate vaccine, pncD, 
and Haemophilus influenzae conjugate vaccine, pRp-D, sharing the carrier 
Dt, may induce interference in infants. presented at the second International 
Symposium on pneumococci and pneumococcal Diseases; march 19–23, 
2000; Sun City, South Africa. Abstract p39.
 37. Käyhty H, Ahman H, eriksson K, et al. Immunogenicity and tolerability of 
a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 
months of age. Pediatr Infect Dis J. 2005;24:108–114.
 38. Kieninger Dm, Kueper K, Steul K, et al.; 006 study group. Safety, tolerabil-
ity, and immunologic noninferiority of a 13-valent pneumococcal conjugate 
vaccine compared to a 7-valent pneumococcal conjugate vaccine given with 
routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
 39. Kim nH, lee J, lee SJ, et al. Immunogenicity and safety of pneumococ-
cal 7-valent conjugate vaccine (diphtheria CRm(197) protein conjugate; 
prevenar) in Korean infants: differences that are found in Asian children. 
Vaccine. 2007;25:7858–7865.
 40. Kim CH, Kim JS, Cha SH, et al. Response to primary and booster vac-
cination with 10-valent pneumococcal nontypeable Haemophilus influen-
zae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 
2011;30:e235–e243.
 41. Knuf m, Habermehl p, Cimino C, et al. Immunogenicity, reactogenicity and 
safety of a 7-valent pneumococcal conjugate vaccine (pCV7) concurrently 
administered with a Dtpa-HBV-IpV/Hib combination vaccine in healthy 
infants. Vaccine. 2006;24:4727–4736.
 42. lagos R, munoz A, levine mm, et al. Immunology of combining CRm(197) 
conjugates for Streptococcus pneumoniae, Neisseria meningitis and 
Haemophilus influenzae in Chilean infants. Vaccine. 2009;27:2299–2305.
 43. lagos Re, muñoz Ae, levine mm, et al. Safety and immunogenicity of 
the 10-valent pneumococcal nontypeable Haemophilus influenzae pro-
tein D conjugate vaccine (pHiD-CV) in Chilean children. Hum Vaccine. 
2011;7:511–522.
 44. lee H, nahm mH, Burton R, et al. Immune response in infants to the hep-
tavalent pneumococcal conjugate vaccine against vaccine-related serotypes 
6A and 19A. Clin Vaccine Immunol. 2009;16:376–381.
 45. li RC, li FX, li Yp, et al. Safety and immunogenicity of a 7-valent pneu-
mococcal conjugate vaccine (prevenar): primary dosing series in healthy 
Chinese infants. Vaccine. 2008;26:2260–2269.
 46. lin tY, lu CY, Chang lY, et al. Immunogenicity and safety of 10-valent 
pneumococcal non-typeable Haemophilus influenzae protein D-conjugate 
vaccine (pHiD-CV) co-administered with routine childhood vaccines in 
taiwan. J Formos Med Assoc. 2012;111:495–503.
 47. mcneely tB, Arena De, Kniskern pJ, et al. Opsonic antibody responses to 
a three dose pn-OmpC conjugate vaccination with a fourth dose boost of 
pn-OmpC conjugate or pneumOVAXa 23. Abstr Intersci Conf Antimicrob 
Agents Chemother. 1997:209.
 48. miernyk Km, parkinson AJ, Rudolph Km, et al. Immunogenicity of a hep-
tavalent pneumococcal conjugate vaccine in Apache and navajo Indian, 
Alaska native, and non-native American children aged <2 years. Clin Infect 
Dis. 2000;31:34–41.
 49. moss SJ, Fenton AC, toomey J, et al. Immunogenicity of a heptavalent con-
jugate pneumococcal vaccine administered concurrently with a combination 
diphtheria, tetanus, five-component acellular pertussis, inactivated polio, 
and Haemophilus influenzae type B vaccine and a meningococcal group 
C conjugate vaccine at 2, 3, and 4 months of age. Clin Vaccine Immunol. 
2010;17:311–316.
 50. nurkka A, Ahman H, Korkeila m, et al. Serum and salivary anti-capsular 
antibodies in infants and children immunized with the heptavalent pneumo-
coccal conjugate vaccine. Pediatr Infect Dis J. 2001;20:25–33.
 51. nurkka A, Ahman H, Yaich m, et al. Serum and salivary anti-capsular anti-
bodies in infants and children vaccinated with octavalent pneumococcal 
conjugate vaccines, pncD and pnct. Vaccine. 2001;20:194–201.
 52. nurkka A, Joensuu J, Henckaerts I, et al. Immunogenicity and safety of the 
eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in 
infants. Pediatr Infect Dis J. 2004;23:1008–1014.
 53. O’Brien Kl, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of 
heptavalent pneumococcal vaccine conjugated to CRm(197) among infants 
with sickle cell disease. pneumococcal Conjugate Vaccine Study Group. 
Pediatrics. 2000;106:965–972.
 54. Obaro SK, Adegbola RA, Chang I, et al. Safety and immunogenicity of a 
nonavalent pneumococcal vaccine conjugated to CRm197 administered 
simultaneously but in a separate syringe with diphtheria, tetanus and pertus-
sis vaccines in Gambian infants. Pediatr Infect Dis J. 2000;19:463–469.
 55. Obaro SK, enwere GC, Deloria m, et al. Safety and immunogenicity of 
pneumococcal conjugate vaccine in combination with diphtheria, tetanus 
toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. 
Pediatr Infect Dis J. 2002;21:940–947.
 56. Olivier C, Belohradsky BH, Stojanov S, et al. Immunogenicity, reactogenic-
ity, and safety of a seven-valent pneumococcal conjugate vaccine (pCV7) 
concurrently administered with a fully liquid Dtpa-IpV-HBV-Hib combina-
tion vaccine in healthy infants. Vaccine. 2008;26:3142–3152.
The Pediatric Infectious Disease Journal • Volume 33, Number 1, Supplement 2, January 2014    Dosing and Immunogenicity
© 2013 Lippincott Williams & Wilkins  www.pidj.com  | S129
 57. Osendarp SJ, prabhakar H, Fuchs GJ, et al. Immunization with the heptava-
lent pneumococcal conjugate vaccine in Bangladeshi infants and effects of 
zinc supplementation. Vaccine. 2007;25:3347–3354.
 58. Ota mO, Akinsola A, townend J, et al. the immunogenicity and impact on 
nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine 
immunization schedule. Vaccine. 2011;29:2999–3007.
 59. pichichero me, Bernstein H, Blatter mm, et al.; 085 Study Investigators. 
Immunogenicity and safety of a combination diphtheria, tetanus toxoid, 
acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadmin-
istered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus 
influenzae type b conjugate vaccine. J Pediatr. 2007;151:43–49, 49.e1.
 60. prymula R, peeters p, Chrobok V, et al. pneumococcal capsular polysaccha-
rides conjugated to protein D for prevention of acute otitis media caused by 
both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a 
randomised double-blind efficacy study. Lancet. 2006;367:740–748.
 61. Reinert p, Guy m, Girier B, et al. [the safety and immunogenicity of an 
heptavalent pneumococcal polysaccharide conjugate vaccine (prevenar) 
administered in association with a whole-cell pertussis-based pediatric 
combination vaccine (Dtp-IpV/pRp-t) to French infants with a two-, 
three-, and four-month schedule]. Arch Pediatr. 2003;10:1048–1055.
 62. Rennels mB, edwards Km, Keyserling Hl, et al. Safety and immunogenic-
ity of heptavalent pneumococcal vaccine conjugated to CRm197 in united 
States infants. Pediatrics. 1998;101(4 pt 1):604–611.
 63. Rodenburg GD, van Gils eJ, Veenhoven RH, et al. Comparability of antibody 
response to a booster dose of 7-valent pneumococcal conjugate vaccine in 
infants primed with either 2 or 3 doses. Vaccine. 2010;28:1391–1396.
 64. Ruggeberg Ju, Collins C, Clarke p, et al. Immunogenicity and induction of 
immunological memory of the heptavalent pneumococcal conjugate vaccine 
in preterm uK infants. Vaccine. 2007;25:264–271.
 65. Ruiz-palacios Gm, Guerrero ml, Hernández-Delgado l, et al. 
Immunogenicity, reactogenicity and safety of the 10-valent pneumococ-
cal nontypeable Haemophilus influenzae protein D conjugate vaccine 
(pHiD-CV) in mexican infants. Hum Vaccine. 2011;7:1137–1145.
 66. Russell Fm, Balloch A, tang ml, et al. Immunogenicity following one, two, 
or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine. 
2009;27:5685–5691.
 67. Schmitt HJ, Faber J, lorenz I, et al. the safety, reactogenicity and immuno-
genicity of a 7-valent pneumococcal conjugate vaccine (7VpnC) concur-
rently administered with a combination Dtap-IpV-Hib vaccine. Vaccine. 
2003;21:3653–3662.
 68. Scott JA, Ojal J, Ashton l, et al. pneumococcal conjugate vaccine given 
shortly after birth stimulates effective antibody concentrations and primes 
immunological memory for sustained infant protection. Clin Infect Dis. 
2011;53:663–670.
 69. Shao pl, lu CY, Chang lY, et al. Safety and immunogenicity of heptava-
lent pneumococcal conjugate vaccine in taiwanese infants. J Formos Med 
Assoc. 2004;103:613–617.
 70. Shapiro eD, Kaplan Sl, Steinhoff mC, et al. Immunogenicity of two pneu-
mococcal conjugate vaccines. Pediatr Res. 1997;41:130.
 71. Shinefield HR, Black S, Ray p, et al. Safety and immunogenicity of hepta-
valent pneumococcal CRm197 conjugate vaccine in infants and toddlers. 
Pediatr Infect Dis J. 1999;18:757–763.
 72. Sigurdardottir St, Davidsdottir K, Arason VA, et al. Safety and immu-
nogenicity of CRm197-conjugated pneumococcal-meningococcal C 
combination vaccine (9vpnC-mnCC) whether given in two or three primary 
doses. Vaccine. 2008;26:4178–4186.
 73. Silfverdal SA, Hogh B, Bergsaker mR, et al. Immunogenicity of a 2-dose 
priming and booster vaccination with the 10-valent pneumococcal nontype-
able Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J. 
2009;28:e276–e282.
 74. Soininen A, lehtonen H, lahdenkari m, et al. Functional activity of anti-
bodies against serotype 19F evoked by pneumococcal conjugate vaccines. 
5th International Symposium on pneumococci and pneumococcal Diseases; 
April 2–6, 2006; Alice Springs, Australia. Abstract 249.
 75. tichmann-Schumann I, Soemantri p, Behre u, et al. Immunogenicity and 
reactogenicity of four doses of diphtheria-tetanus-three-component acel-
lular pertussis-hepatitis B-inactivated polio virus-Haemophilus influen-
zae type b vaccine coadministered with 7-valent pneumococcal conjugate 
Vaccine. Pediatr Infect Dis J. 2005;24:70–77.
 76. Vesikari t, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent 
pneumococcal non-typeable Haemophilus influenzae protein D conjugate 
vaccine (pHiD-CV) compared to the licensed 7vCRm vaccine. Pediatr 
Infect Dis J. 2009;28(4 suppl):S66–S76.
 77. Wysocki J, tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent 
pneumococcal non-typeable Haemophilus influenzae protein D conju-
gate vaccine (pHiD-CV) when coadministered with different neisse-
ria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 
2009;28(4 suppl):S77–S88.
 78. Zangwill Km, Greenberg Dp, Chiu CY, et al. Safety and immunogenic-
ity of a heptavalent pneumococcal conjugate vaccine in infants. Vaccine. 
2003;21:1894–1900.
 79. united nations. Composition of macro geographical (continental) regions, 
geographical sub-regions, and selected economic and other groupings 
Available at: http://unstats.un.org/unsd/methods/m49/m49regin.htm. Accessed 
August 13, 2013.
 80. park De, Deloria Knoll m, Johnson tS, et al. the differential impact of 
coadministered vaccines, geographic region, vaccine product and other 
covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr 
Infect Dis J. 2014;33 (Suppl 2):S130–S139.
 81. Scott p, Rutjes AW, Bermetz l, et al. Comparing pneumococcal conjugate 
vaccine schedules based on 3 and 2 primary doses: systematic review and 
meta-analysis. Vaccine. 2011;29:9711–9721.
 82. Goldblatt D, Hussain m, Andrews n, et al. Antibody responses to naso-
pharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal 
household study. J Infect Dis. 2005;192:387–393.
 83. Dagan R, Givon-lavi n, Fraser D, et al. Serum serotype-specific pneumo-
coccal anticapsular immunoglobulin g concentrations after immunization 
with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyn-
geal acquisition of pneumococcus. J Infect Dis. 2005;192:367–376.
 84. millar eV, O’Brien Kl, Bronsdon mA, et al. Anticapsular serum antibody 
concentration and protection against pneumococcal colonization among 
children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin 
Infect Dis. 2007;44:1173–1179.
 85. Santosham m, Reid R, Chandran A, et al. Contributions of native 
Americans to the global control of infectious diseases. Vaccine. 
2007;25:2366–2374.
 86. Optimizing pneumococcal conjugate vaccine (pCV) schedules. Wkly 
Epidemiol Rec. 2012;87:13–15. 
